Feature Article

Addressing Cardiovascular Risks in Psoriasis: Guidance for Clinical Practice

By

Psoriasis is often comorbid with cardiovascular disorders and tends to have a dose-response relationship with its metabolic comorbidities.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Psoriasis

Bryhali Lotion Gets Tentative Approval for Plaque Psoriasis

By October 19, 2018

The approval of Bryhali was based on data from 2 randomized, double-blind studies conducted in 430 patients with moderate to severe plaque psoriasis.

Psoriasis

Safety Outcomes Associated With Apremilast Use in Psoriasis

By October 19, 2018

Investigators examined long-term safety during weeks 16 to 52 of apremilast in patients with psoriasis.

Psoriasis

Aortic Vascular Inflammation Associated With Coronary Artery Disease in Psoriasis

By October 19, 2018

Aortic vascular inflammation is a potential precursor to early coronary artery disease in patients with psoriasis.

Psoriasis

Psoriasis Associated With Clinical Signs of Accelerated Atherosclerosis

By October 18, 2018

The findings could corroborate existing evidence on how changes in serum ACE, the renin-angiotensin system, and vascular endothelium metabolism may be linked to atherosclerosis in psoriasis.

Psoriasis

Halobetasol/Tazarotene Provides Relief for Moderate to Severe Psoriasis

By October 16, 2018

Investigators examine the efficacy and tolerability of halobetasol/tazarotene within the first 2 weeks of treatment.

Psoriasis

Halobetasol Propionate Lotion Shows Efficacy for Tx of Psoriasis

October 16, 2018

Halobetasol propionate 0.01 percent lotion appears safe and effective for the treatment of moderate-to-severe plaque psoriasis.

Psoriasis

TYK2 Inhibitor Clears Psoriasis Over 12 Weeks

October 15, 2018

Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks.

Psoriasis

Adjunctive Topical Foam Plus Biologics Effective for Refractory Psoriasis

By October 09, 2018

All participants had been treated with biologic therapies for more than 24 weeks and had not obtained adequate response.

Psoriasis

Guselkumab Effective for Long-Term Treatment of Moderate to Severe Psoriasis

By October 09, 2018

Sustained-response treatments are of great importance in chronic conditions like psoriasis.

Psoriasis

Risankizumab May Be More Effective Than Ustekinumab for Plaque Psoriasis

By Dermatology Advisor Contributing Writer October 08, 2018

Patients with moderate to severe plaque psoriasis from 2 replicate, phase 3, randomized, double-blind, placebo-controlled, and active comparator-controlled trials were included in the analysis.

Sign up for Newsletters